GSK acquires Nuvalent for $10.6 billion in oncology push

GSK agreed to get Nuvalent, a Boston-based clinical-stage biopharmaceutical institution focused connected lung crab treatments, for $10.6 cardinal successful an all-cash deal, the institution said Tuesday.

At $124 per share, the connection represents a 40% premium implicit what Nuvalent shares fetched astatine Monday's close, the institution said. Investors sent Nuvalent shares up astir 39% successful premarket U.S. trading, portion GSK shares dropped much than 3% connected the London Stock Exchange.

The acquisition is GSK's largest successful much than a decade, according to CNBC. Through the transaction, GSK would summation 3 non-small compartment lung crab programs successful total. Regulatory decisions from the FDA connected the 2 frontrunners — zidesamtinib, which targets ROS1 mutations, and neladalkib, an ALK inhibitor — are anticipated connected Sept. 18 and Nov. 27, 2026, respectively, according to the company. A 3rd asset, NVL-330, is simply a HER2 inhibitor successful signifier I trials.

"The 2 pb products are imaginable best-in-class assets that could motorboat this twelvemonth if approved by the FDA and connection important caller attraction options to patients with 2 forms of non-small compartment lung cancer," GSK CEO Luke Miels said successful a statement.

GSK's existing 2026 full-year guidance remains unchanged, and the institution projects the woody volition statesman lifting gross and halfway operating nett starting successful 2027, with a affirmative interaction connected halfway net per stock pursuing successful 2029. Net of currency acquired, GSK's aggregate concern is estimated astatine $9.4 billion. The transaction volition beryllium funded chiefly from caller and existing indebtedness facilities positive cash, with nary expected interaction to GSK's recognition rating.

For Miels, who stepped into the CEO relation astatine the opening of 2026 succeeding Emma Walmsley, the acquisition represents a notable departure from his earlier stated approach, according to Reuters. He had signaled to investors a penchant for keeping deals wrong a £2 cardinal to £4 cardinal range. Speaking with reporters, Miels argued the terms tag was warranted fixed that the acquisition amounts to purchasing 3 chiseled products done a azygous deal.

GSK said the woody volition besides accelerate its introduction into lung crab and make a level for enlargement with Ris-Rez, its B7-H3 antibody-drug conjugate presently successful signifier III objective development. The institution said the acquisition is expected to assistance fortify halfway operating nett done the dolutegravir nonaccomplishment of exclusivity play from 2028 to 2030.

Subject to regulatory approvals, including clearance nether the Hart-Scott-Rodino Act, the companies expect to finalize the transaction earlier the extremity of the 3rd 4th of 2026.